Identification of low-molecular-weight compounds inhibiting growth of corynebacteria: Potential lead compounds for antibiotics

Jaime L. Stark, Jennifer C. Copeland, Alexander Eletsky, Greg A Somerville, Thomas Szyperski, Robert Powers

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The bacterial genus Corynebacteria contains several pathogenic species that cause diseases such as diphtheria in humans and "cheesy gland" in goats and sheep. Thus, identifying new therapeutic targets to treat Corynebacteria infections is both medically and economically important. CG2496, a functionally uncharacterized protein from Corynebacterium glutamicum, was evaluated using an NMR ligand-affinity screen. A total of 11 compounds from a library of 460 biologically active compounds were shown to selectively bind CG2496 in a highly conserved region of the protein. The best binder was identified to be methiothepin (KD=5419 mm), an FDA-approved serotonin receptor antagonist. Methiothepin was also shown to inhibit the growth of C. glutamicum, but not bacteria that lack CG2496 homologs. Our results suggest that CG2496 is a novel therapeutic target and methiothepin is a potential lead compound or structural scaffold for developing new antibiotics specifically targeting Corynebacteria.

Original languageEnglish (US)
Pages (from-to)282-285
Number of pages4
JournalChemMedChem
Volume9
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Methiothepin
Lead compounds
Corynebacterium
Corynebacterium glutamicum
Molecular Weight
Molecular weight
Anti-Bacterial Agents
Corynebacterium Infections
Growth
Serotonin Antagonists
Diphtheria
Goats
Scaffolds
Binders
Sheep
Bacteria
Proteins
Nuclear magnetic resonance
Ligands
Therapeutics

Keywords

  • Antibiotics
  • Corynebacteria
  • Drug Discovery
  • Fast-Nmr
  • Nmr Spectroscopy

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry

Cite this

Identification of low-molecular-weight compounds inhibiting growth of corynebacteria : Potential lead compounds for antibiotics. / Stark, Jaime L.; Copeland, Jennifer C.; Eletsky, Alexander; Somerville, Greg A; Szyperski, Thomas; Powers, Robert.

In: ChemMedChem, Vol. 9, No. 2, 02.2014, p. 282-285.

Research output: Contribution to journalArticle

Stark, Jaime L. ; Copeland, Jennifer C. ; Eletsky, Alexander ; Somerville, Greg A ; Szyperski, Thomas ; Powers, Robert. / Identification of low-molecular-weight compounds inhibiting growth of corynebacteria : Potential lead compounds for antibiotics. In: ChemMedChem. 2014 ; Vol. 9, No. 2. pp. 282-285.
@article{35a7e77b8e04407eafe9f01bba92bc5d,
title = "Identification of low-molecular-weight compounds inhibiting growth of corynebacteria: Potential lead compounds for antibiotics",
abstract = "The bacterial genus Corynebacteria contains several pathogenic species that cause diseases such as diphtheria in humans and {"}cheesy gland{"} in goats and sheep. Thus, identifying new therapeutic targets to treat Corynebacteria infections is both medically and economically important. CG2496, a functionally uncharacterized protein from Corynebacterium glutamicum, was evaluated using an NMR ligand-affinity screen. A total of 11 compounds from a library of 460 biologically active compounds were shown to selectively bind CG2496 in a highly conserved region of the protein. The best binder was identified to be methiothepin (KD=5419 mm), an FDA-approved serotonin receptor antagonist. Methiothepin was also shown to inhibit the growth of C. glutamicum, but not bacteria that lack CG2496 homologs. Our results suggest that CG2496 is a novel therapeutic target and methiothepin is a potential lead compound or structural scaffold for developing new antibiotics specifically targeting Corynebacteria.",
keywords = "Antibiotics, Corynebacteria, Drug Discovery, Fast-Nmr, Nmr Spectroscopy",
author = "Stark, {Jaime L.} and Copeland, {Jennifer C.} and Alexander Eletsky and Somerville, {Greg A} and Thomas Szyperski and Robert Powers",
year = "2014",
month = "2",
doi = "10.1002/cmdc.201300386",
language = "English (US)",
volume = "9",
pages = "282--285",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Identification of low-molecular-weight compounds inhibiting growth of corynebacteria

T2 - Potential lead compounds for antibiotics

AU - Stark, Jaime L.

AU - Copeland, Jennifer C.

AU - Eletsky, Alexander

AU - Somerville, Greg A

AU - Szyperski, Thomas

AU - Powers, Robert

PY - 2014/2

Y1 - 2014/2

N2 - The bacterial genus Corynebacteria contains several pathogenic species that cause diseases such as diphtheria in humans and "cheesy gland" in goats and sheep. Thus, identifying new therapeutic targets to treat Corynebacteria infections is both medically and economically important. CG2496, a functionally uncharacterized protein from Corynebacterium glutamicum, was evaluated using an NMR ligand-affinity screen. A total of 11 compounds from a library of 460 biologically active compounds were shown to selectively bind CG2496 in a highly conserved region of the protein. The best binder was identified to be methiothepin (KD=5419 mm), an FDA-approved serotonin receptor antagonist. Methiothepin was also shown to inhibit the growth of C. glutamicum, but not bacteria that lack CG2496 homologs. Our results suggest that CG2496 is a novel therapeutic target and methiothepin is a potential lead compound or structural scaffold for developing new antibiotics specifically targeting Corynebacteria.

AB - The bacterial genus Corynebacteria contains several pathogenic species that cause diseases such as diphtheria in humans and "cheesy gland" in goats and sheep. Thus, identifying new therapeutic targets to treat Corynebacteria infections is both medically and economically important. CG2496, a functionally uncharacterized protein from Corynebacterium glutamicum, was evaluated using an NMR ligand-affinity screen. A total of 11 compounds from a library of 460 biologically active compounds were shown to selectively bind CG2496 in a highly conserved region of the protein. The best binder was identified to be methiothepin (KD=5419 mm), an FDA-approved serotonin receptor antagonist. Methiothepin was also shown to inhibit the growth of C. glutamicum, but not bacteria that lack CG2496 homologs. Our results suggest that CG2496 is a novel therapeutic target and methiothepin is a potential lead compound or structural scaffold for developing new antibiotics specifically targeting Corynebacteria.

KW - Antibiotics

KW - Corynebacteria

KW - Drug Discovery

KW - Fast-Nmr

KW - Nmr Spectroscopy

UR - http://www.scopus.com/inward/record.url?scp=84897025233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897025233&partnerID=8YFLogxK

U2 - 10.1002/cmdc.201300386

DO - 10.1002/cmdc.201300386

M3 - Article

C2 - 24403054

AN - SCOPUS:84897025233

VL - 9

SP - 282

EP - 285

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 2

ER -